source
- Sellas Life Sciences reports Phase 3 success for AML vaccine galinpepimut-SSellas Life Sciences announced on Tuesday that its experimental cancer vaccine achieved a positive outcome in a Phase 3 study. The trial enrolled patients with a specific form of acute myeloid leu…
- FDA rejects Summit’s ivonescimab, citing China‑centric data and missed survival benefitThe FDA sent Summit Therapeutics a complete response letter on Nov 13, rejecting its PD‑1×VEGF bispecific antibody ivonescimab. Reviewers said the pivotal HARMONi trial was dominated by patients f…